Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles.

B Jiang1, M K Estes, C Barone

  • 1Wyeth-Lederle Vaccines and Pediatrics, Pearl River, NY 10965, USA.

Vaccine
|March 6, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity-driven thyroid cancer burden in middle-aged and older populations: temporal trends and projected trajectories based on the Global Burden of Disease study.

Hong Kong medical journal = Xianggang yi xue za zhi·2026
Same author

Separate Exact Laws of Kinetic and Magnetic Energy Cascade in Magnetohydrodynamic Turbulence.

Physical review letters·2026
Same author

A comparative study of vessel length measurements in branches of eight subtropical woody species based on three methods.

Plant biology (Stuttgart, Germany)·2026
Same author

Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

[Clinical efficacy of 12 o'clock peripheral iridectomy in aphakic eyes undergoing pars plana vitrectomy with heavy silicone oil tamponade].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2026
Same author

The use of coronary computed tomography angiography (CCTA) to predict coronary artery plaque, with a focus on new, high-risk, and obstructive plaques.

Clinical radiology·2025

Rotavirus virus-like particle (VLP) vaccines, particularly with the QS-21 adjuvant, show promise for preventing rotavirus infections. The adjuvant type significantly impacts immune response and protection against rotavirus challenge.

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Rotavirus is a leading cause of severe diarrheal disease in infants worldwide.
  • Existing vaccines have limitations, necessitating the development of novel and effective vaccine strategies.
  • Virus-like particles (VLPs) offer a promising platform for rotavirus vaccine development due to their non-replicating nature.

Purpose of the Study:

  • To evaluate the immunogenicity and protective efficacy of rotavirus VLPs in a mouse model.
  • To compare the effects of different adjuvants (QS-21 and AlOH) on VLP vaccine responses.
  • To assess the potential of VLP vaccines for preventing rotavirus infections.

Main Methods:

  • Production of rotavirus VLPs (G1 and G3 serotypes) in insect cells using recombinant baculoviruses.
Keywords:
Non-programmatic

Related Experiment Videos

  • Vaccination of mice with VLPs formulated with QS-21 or AlOH, or alone.
  • Assessment of serum and fecal antibody responses using ELISA and microneutralization assays.
  • Evaluation of protective efficacy against rotavirus challenge by measuring fecal antigen shedding.

    • Main Results:

    • QS-21 adjuvant significantly enhanced serum and intestinal antibody responses to both G1 and G3 VLPs compared to AlOH or no adjuvant.
    • QS-21 induced a balanced Th1/Th2 immune response, while AlOH induced a predominant Th2 response.
    • G3 VLPs with QS-21 provided complete protection (100%) against rotavirus challenge, while G1 VLPs with QS-21 provided partial protection (88%).
    • AlOH-formulated G1 VLPs offered minimal protection (1%).

    Conclusions:

    • The choice of adjuvant critically influences the immunogenicity and protective efficacy of rotavirus VLP vaccines.
    • QS-21 is a potent adjuvant for rotavirus VLP vaccines, inducing robust and protective immune responses.
    • These findings support the development of parenteral rotavirus VLP vaccines for disease prevention.